GLAXF GSK plc
Price Chart
Executive Summary
GSK's investigational liver therapy, efimosfermin, has received FDA Breakthrough Therapy and EMA PRIME designations for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), based on Phase II data showing improvement in liver fibrosis and MASH resolution. These designations accelerate development and review pathways, recognizing efimosfermin's potential to address a significant unmet medical need in a disease with no approved therapies for advanced stages.
Actionable Insight
This regulatory momentum meaningfully de-risks efimosfermin's development path and enhances GSK's hepatology franchise value. Traders should monitor upcoming Phase III readouts as key catalysts, particularly ZENITH-1/2 data, which could confirm clinical efficacy and support accelerated approval. Positive results may re-rate GSK's biopharma valuation, especially given the lack of current F4 treatment options.
Key Facts
- Efimosfermin granted FDA Breakthrough Therapy and EMA PRIME designations for MASH treatment
- Phase II data at 48 weeks showed fibrosis improvement and MASH resolution in F2/F3 patients versus placebo
- Efimosfermin has a well-tolerated safety profile with mild, transient adverse events (nausea, vomiting, diarrhea)
- Phase III trials (ZENITH-1 and ZENITH-2) ongoing for F2/F3 fibrosis; Phase III trials for F4 (cirrhotic) patients expected to start in 2026
- MASH affects up to 5% of the global population and is a leading cause of liver transplants in the US and Europe
- No approved treatments currently exist for cirrhotic MASH (F4)
Financial Impact
High long-term value potential; MASH market projected to exceed $20 billion by 2030 if effective therapies are approved
Risk Factors
- Phase III trials may not replicate Phase II efficacy
- Safety profile could worsen in larger, longer trials
- Competitive landscape may evolve with other MASH therapies in development
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-003947 |
| Document: 0001654954-26-003947-index-headers.html | 0001654954-26-003947 |
| Document: 0001654954-26-003947-index.html | 0001654954-26-003947 |
| Document: 0001654954-26-003947.txt | 0001654954-26-003947 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 9, 2026
today
|
6-K
| — | awaiting T+5 | — | — |
|
Jun 9, 2026
today
|
6-K
| — | awaiting T+5 | — | — |
|
Jun 1, 2026
8d ago
|
6-K
| $24.25 $24.66 | ▲ +1.69% | ▲ +4.44% | $24.66 (+1.69%) |
|
Jun 1, 2026
8d ago
|
6-K
| $24.25 $24.66 | ▲ +1.69% | ▲ +4.44% | $24.66 (+1.69%) |
|
May 28, 2026
12d ago
|
6-K
| $24.58 $24.66 | ▲ +0.33% | ▲ +0.01% | $24.66 (+0.33%) |
|
May 27, 2026
13d ago
|
6-K
| $25.57 $23.94 | ▼ −6.37% | ▼ −7.58% | $24.66 (−3.56%) |
|
May 26, 2026
14d ago
|
6-K
| $25.50 $24.25 | ▼ −4.90% | ▼ −5.99% | $24.66 (−3.29%) |
|
May 26, 2026
14d ago
|
6-K
| $25.50 $24.25 | ▼ −4.90% | ▼ −5.99% | $24.66 (−3.29%) |
|
May 22, 2026
18d ago
|
6-K
| $26.00 $24.25 | ▼ −6.73% | ▼ −8.39% | $24.66 (−5.15%) |
|
May 20, 2026
20d ago
|
6-K
| $25.70 $25.57 | ▼ −0.51% | ▼ −1.74% | $24.66 (−4.05%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access